The current study is a review of the literature on patients with diabetes who are diagnosed with colorectal cancer (CRC), encompassing recent research on CRC and the molecular level changes occurring in these patients on the basis of varying environmental as well as non-environmental factors. It has been noted that nearly 50% of all patients undergo the systemic treatment module; however, most of them exhibit drug resistance. In addition, targeted gene therapy has also been used in treatment but has been found to be effective only in patients with a specified molecular profile (or else this might lead to an increased risk of developing resistant mutations). This has led to increasing interest among researchers in finding innovative treatment options. Metformin, a biguanide, has been widely used in treating diabetes. The drug has been reportedly used in cases of hypothesis-generating retrospective population studies of diabetic patients showing reduced incidence of cancer. Metformin helps in reduction of excess insulin levels that possess various effects on cell signaling and metabolism. Nonetheless, there is need for an in-depth study on its molecular mechanism to fill any existing research gaps.

中文翻译：

---

二甲双胍：糖尿病患者大肠癌治疗的有益候选者。

当前的研究是对有关被诊断为大肠癌（CRC）的糖尿病患者的文献的综述，涵盖了有关CRC和这些患者因环境和非环境因素变化而发生的分子水平变化的最新研究。 。已经注意到，几乎所有患者中有50％接受了全身治疗。然而，它们大多数表现出耐药性。另外，靶向基因疗法也已用于治疗中，但已发现仅在具有特定分子谱的患者中有效（否则这可能导致产生耐药突变的风险增加）。这导致研究人员对寻找创新治疗方案的兴趣日益浓厚。二甲双胍，一种双胍，已被广泛用于治疗糖尿病。据报道，该药物已用于糖尿病患者的假说生成回顾性人群研究中，显示癌症发生率降低。二甲双胍有助于减少多余的胰岛素水平，而胰岛素水平过高会对细胞信号传导和代谢产生各种影响。尽管如此，仍需要对其分子机制进行深入研究，以填补任何现有的研究空白。